Nanotechnology Drug Delivery

For hydrophobic drugs, proteins and nucleic acids

The Drug Delivery Problem

There are a number of small molecules which, without appropriate nanotechnology delivery systems, could not otherwise be delivered due to their excessive toxicity, poor oral bioavailability, poor solubility in biological fluids, inappropriate pharmacokinetics, and lack of efficacy within a tolerable dose range. Nanotechnology can be used for the oral delivery of biotechnology drugs that are usually delivered by daily injections or intravenously in a hospital setting. Nanotechnology also provides for passive and active targeting the drug to the disease site.

Nanotechnology drug delivery allows the reformulation of existing drugs to provide improved and sustained or time-released delivery, often repositioning and/or repurposing the drug and extending its lifecycle.

Aphios' Drug Delivery Solutions

Our enabling nanotechnologies for the enhanced delivery of therapeutics ranging from large macromolecules to potent but water-insoluble small molecules include:

  • Phospholipid Nanosomes for the intravenous or topical administration of proteins, genes, siRNA, hydrophilic molecules and hydrophobic anticancer drugs
  • Polymer Nanospheres for oral/depot/intravenous delivery of proteins and hydrophobic molecules, and controlled-release small molecules and vaccine antigens
  • Protein Nanoparticles for oral/subcutaneous/pulmonary delivery of hydrophobic drugs, proteins, peptides, genes and vaccine antigens

Advantages and Applications

The key advantage and differentiator of our drug delivery platforms is that they do not utilize organic solvents which could denature the target molecule being encapsulated and/or leave residual toxic organic solvents in the nanoparticles. Additionally, the technologies are environment-friendly, scalable and can be operated in a continuous flow mode.

We are utilizing these nanotechnology drug delivery platforms for the development of several enhanced therapeutic products. We will partner with pharmaceutical and biotechnology companies to improve the delivery of novel drug candidates or to reformulate existing drugs.